In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

Centromeres, specialized regions located at the center of chromosomes, are critical for ensuring proper cell division. During ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Molecular characterization of an extensive lung cancer patient-derived xenograft (PDX) resource.

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

The global ablation technology market was valued at US$ 6.82 billion in 2024 and is projected to reach US$ 16.74 billion by ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a ...

OX-4224 is an investigational oral small molecule that targets the PD-1/PD-L1 immune checkpoint pathway and offers a potentially more accessible and cost-effective option compared to existing ...

State Key Laboratory of Drug Research and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China ...

Uniquely, however, BNT327 targets the PD-L1 ligand, as opposed to the PD-1 receptor, which the current VEGF bispecific frontrunner ivonescimab—developed by Summit Therapeutics and Chinese partner ...